Ekso Bionics (NASDAQ:EKSO) Now Covered by StockNews.com

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report issued on Friday. The firm issued a hold rating on the stock.

EKSO has been the topic of several other reports. HC Wainwright reduced their price target on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. Lake Street Capital cut their target price on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th.

Ekso Bionics Price Performance

Shares of NASDAQ:EKSO opened at $0.57 on Friday. Ekso Bionics has a one year low of $0.50 and a one year high of $3.13. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. The company has a market cap of $12.47 million, a price-to-earnings ratio of -0.87 and a beta of 1.43. The firm has a 50 day simple moving average of $0.84 and a 200 day simple moving average of $1.02.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The firm had revenue of $4.13 million during the quarter, compared to the consensus estimate of $6.00 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. During the same quarter in the previous year, the company posted ($0.24) earnings per share. Research analysts predict that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.